APO Research
Talk to an analyst

APO RESEARCH · REPORT

Acute Hepatic Porphyria Drug

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Acute Hepatic Porphyria Drug Market Analysis and Forecast 2026-2032

2 January 2026197 pages

Choose your research edition.

Industry ResearchAcute Hepatic Porphyria Drug Industry Research Report 2026108 pages · $2,950 USDIndustry Growth & TrendsGlobal Acute Hepatic Porphyria Drug Industry Growth and Trends Forecast to 203261 pages · $3,450 USDMarket StructureGlobal Acute Hepatic Porphyria Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032179 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Acute Hepatic Porphyria Drug Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Acute Hepatic Porphyria Drug Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Acute Hepatic Porphyria Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Acute Hepatic Porphyria Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Acute Hepatic Porphyria Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Acute Hepatic Porphyria Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Acute Hepatic Porphyria Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Acute Hepatic Porphyria Drug include Alnylam Pharmaceuticals and Recordati Rare Diseases etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Acute Hepatic Porphyria Drug, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Acute Hepatic Porphyria Drug, also provides the revenue of main regions and countries. Of the upcoming market potential for Acute Hepatic Porphyria Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Acute Hepatic Porphyria Drug revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Acute Hepatic Porphyria Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Acute Hepatic Porphyria Drug revenue, projected growth trends, production technology, application and end-user industry.

Acute Hepatic Porphyria Drug Segment by Company

Alnylam Pharmaceuticals

Recordati Rare Diseases

Acute Hepatic Porphyria Drug Segment by Type

350 Mg

313 Mg

Acute Hepatic Porphyria Drug Segment by Application

Retail Pharmacy

Online Pharmacy

Hospital Pharmacy

Others

Acute Hepatic Porphyria Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Acute Hepatic Porphyria Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Acute Hepatic Porphyria Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Acute Hepatic Porphyria Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Acute Hepatic Porphyria Drug in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Acute Hepatic Porphyria Drug company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Acute Hepatic Porphyria Drug revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Acute Hepatic Porphyria Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. 350 Mg Major Player Table 3. 313 Mg Major Player Table 4. Global Acute Hepatic Porphyria Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Retail Pharmacy Major Player Table 6. Online Pharmacy Major Player Table 7. Hospital Pharmacy Major Player Table 8. Others Major Player Table 9. Acute Hepatic Porphyria Drug Industry Trends Table 10. Acute Hepatic Porphyria Drug Industry Drivers Table 11. Acute Hepatic Porphyria Drug Industry Opportunities and Challenges Table 12. Acute Hepatic Porphyria Drug Industry Restraints Table 13. Global Acute Hepatic Porphyria Drug Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global Acute Hepatic Porphyria Drug Market Size by Region (2021-2026) & (US$ Million) Table 15. Global Acute Hepatic Porphyria Drug Market Share by Region (2021-2026) Table 16. Global Acute Hepatic Porphyria Drug Market Size by Region (2027-2032) & (US$ Million) Table 17. Global Acute Hepatic Porphyria Drug Market Share by Region (2027-2032) Table 18. Global Acute Hepatic Porphyria Drug Revenue by Players (US$ Million) & (2021-2026) Table 19. Global Acute Hepatic Porphyria Drug Revenue Market Share by Players (2021-2026) Table 20. Global Acute Hepatic Porphyria Drug Key Players Ranking, 2024 VS 2025 VS 2026 Table 21. Global Acute Hepatic Porphyria Drug Key Players Headquarters & Area Served Table 22. Global Acute Hepatic Porphyria Drug Players, Product Type & Application Table 23. Global Acute Hepatic Porphyria Drug Players Establishment Date Table 24. Global Players Market Concentration Ratio (CR5 and HHI) Table 25. Global Acute Hepatic Porphyria Drug by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 26. Global Acute Hepatic Porphyria Drug Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Acute Hepatic Porphyria Drug Revenue by Type (2021-2026) & (US$ Million) Table 28. Global Acute Hepatic Porphyria Drug Revenue by Type (2027-2032) & (US$ Million) Table 29. Global Acute Hepatic Porphyria Drug Revenue Market Share by Type (2021-2026) Table 30. Global Acute Hepatic Porphyria Drug Revenue Market Share by Type (2027-2032) Table 31. Global Acute Hepatic Porphyria Drug Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Acute Hepatic Porphyria Drug Revenue by Application (2021-2026) & (US$ Million) Table 33. Global Acute Hepatic Porphyria Drug Revenue by Application (2027-2032) & (US$ Million) Table 34. Global Acute Hepatic Porphyria Drug Revenue Market Share by Application (2021-2026) Table 35. Global Acute Hepatic Porphyria Drug Revenue Market Share by Application (2027-2032) Table 36. Alnylam Pharmaceuticals Company Information Table 37. Alnylam Pharmaceuticals Business Overview Table 38. Alnylam Pharmaceuticals Acute Hepatic Porphyria Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. Alnylam Pharmaceuticals Acute Hepatic Porphyria Drug Product Portfolio Table 40. Alnylam Pharmaceuticals Recent Development Table 41. Recordati Rare Diseases Company Information Table 42. Recordati Rare Diseases Business Overview Table 43. Recordati Rare Diseases Acute Hepatic Porphyria Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. Recordati Rare Diseases Acute Hepatic Porphyria Drug Product Portfolio Table 45. Recordati Rare Diseases Recent Development Table 46. North America Acute Hepatic Porphyria Drug Revenue by Type (2021-2026) & (US$ Million) Table 47. North America Acute Hepatic Porphyria Drug Revenue by Type (2027-2032) & (US$ Million) Table 48. North America Acute Hepatic Porphyria Drug Revenue by Application (2021-2026) & (US$ Million) Table 49. North America Acute Hepatic Porphyria Drug Revenue by Application (2027-2032) & (US$ Million) Table 50. North America Acute Hepatic Porphyria Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 51. North America Acute Hepatic Porphyria Drug Revenue by Country (2021-2026) & (US$ Million) Table 52. North America Acute Hepatic Porphyria Drug Revenue by Country (US$ Million) & (2027-2032) Table 53. Europe Acute Hepatic Porphyria Drug Revenue by Type (2021-2026) & (US$ Million) Table 54. Europe Acute Hepatic Porphyria Drug Revenue by Type (2027-2032) & (US$ Million) Table 55. Europe Acute Hepatic Porphyria Drug Revenue by Application (2021-2026) & (US$ Million) Table 56. Europe Acute Hepatic Porphyria Drug Revenue by Application (2027-2032) & (US$ Million) Table 57. Europe Acute Hepatic Porphyria Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 58. Europe Acute Hepatic Porphyria Drug Revenue by Country (2021-2026) & (US$ Million) Table 59. Europe Acute Hepatic Porphyria Drug Revenue by Country (US$ Million) & (2027-2032) Table 60. China Acute Hepatic Porphyria Drug Revenue by Type (2021-2026) & (US$ Million) Table 61. China Acute Hepatic Porphyria Drug Revenue by Type (2027-2032) & (US$ Million) Table 62. China Acute Hepatic Porphyria Drug Revenue by Application (2021-2026) & (US$ Million) Table 63. China Acute Hepatic Porphyria Drug Revenue by Application (2027-2032) & (US$ Million) Table 64. Asia Acute Hepatic Porphyria Drug Revenue by Type (2021-2026) & (US$ Million) Table 65. Asia Acute Hepatic Porphyria Drug Revenue by Type (2027-2032) & (US$ Million) Table 66. Asia Acute Hepatic Porphyria Drug Revenue by Application (2021-2026) & (US$ Million) Table 67. Asia Acute Hepatic Porphyria Drug Revenue by Application (2027-2032) & (US$ Million) Table 68. Asia Acute Hepatic Porphyria Drug Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 69. Asia Acute Hepatic Porphyria Drug Revenue by Region (US$ Million) & (2021-2026) Table 70. Asia Acute Hepatic Porphyria Drug Revenue by Region (US$ Million) & (2027-2032) Table 71. SAMEA Acute Hepatic Porphyria Drug Revenue by Type (2021-2026) & (US$ Million) Table 72. SAMEA Acute Hepatic Porphyria Drug Revenue by Type (2027-2032) & (US$ Million) Table 73. SAMEA Acute Hepatic Porphyria Drug Revenue by Application (2021-2026) & (US$ Million) Table 74. SAMEA Acute Hepatic Porphyria Drug Revenue by Application (2027-2032) & (US$ Million) Table 75. SAMEA Acute Hepatic Porphyria Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 76. SAMEA Acute Hepatic Porphyria Drug Revenue by Country (2021-2026) & (US$ Million) Table 77. SAMEA Acute Hepatic Porphyria Drug Revenue by Country (US$ Million) & (2027-2032) Table 78. Research Programs/Design for This Report Table 79. Authors List of This Report Table 80. Secondary Sources Table 81. Primary Sources List of Figures Figure 1. Acute Hepatic Porphyria Drug Image Figure 2. Global Acute Hepatic Porphyria Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Acute Hepatic Porphyria Drug Market Size Share 2021 VS 2025 VS 2032 Figure 4. 350 Mg Image Figure 5. 313 Mg Image Figure 6. Global Acute Hepatic Porphyria Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Acute Hepatic Porphyria Drug Market Size Share 2021 VS 2025 VS 2032 Figure 8. Retail Pharmacy Image Figure 9. Online Pharmacy Image Figure 10. Hospital Pharmacy Image Figure 11. Others Image Figure 12. Global Acute Hepatic Porphyria Drug Market Size (US$ Million) & (2021-2032) Figure 13. Global Acute Hepatic Porphyria Drug Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Acute Hepatic Porphyria Drug Market Share by Region: 2021 VS 2025 VS 2032 Figure 15. Global Acute Hepatic Porphyria Drug Players Revenue Share Top 10 and Top 5 in 2025 Figure 16. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global Acute Hepatic Porphyria Drug Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Acute Hepatic Porphyria Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Acute Hepatic Porphyria Drug Revenue Market Share by Type (2021-2032) Figure 20. Global Acute Hepatic Porphyria Drug Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Acute Hepatic Porphyria Drug Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 22. Global Acute Hepatic Porphyria Drug Revenue Market Share by Application (2021-2032) Figure 23. North America Acute Hepatic Porphyria Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 24. North America Acute Hepatic Porphyria Drug Revenue Share by Type (2021-2032) Figure 25. North America Acute Hepatic Porphyria Drug Revenue Share by Application (2021-2032) Figure 26. North America Acute Hepatic Porphyria Drug Revenue Share by Country (2021-2032) Figure 27. United States Acute Hepatic Porphyria Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Canada Acute Hepatic Porphyria Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Mexico Acute Hepatic Porphyria Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Europe Acute Hepatic Porphyria Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 31. Europe Acute Hepatic Porphyria Drug Revenue Share by Type (2021-2032) Figure 32. Europe Acute Hepatic Porphyria Drug Revenue Share by Application (2021-2032) Figure 33. Europe Acute Hepatic Porphyria Drug Revenue Share by Country (2021-2032) Figure 34. Germany Acute Hepatic Porphyria Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. France Acute Hepatic Porphyria Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. U.K. Acute Hepatic Porphyria Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Italy Acute Hepatic Porphyria Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Spain Acute Hepatic Porphyria Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Russia Acute Hepatic Porphyria Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Netherlands Acute Hepatic Porphyria Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Nordic Countries Acute Hepatic Porphyria Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. China Acute Hepatic Porphyria Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 43. China Acute Hepatic Porphyria Drug Revenue Share by Type (2021-2032) Figure 44. China Acute Hepatic Porphyria Drug Revenue Share by Application (2021-2032) Figure 45. Asia Acute Hepatic Porphyria Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. Asia Acute Hepatic Porphyria Drug Revenue Share by Type (2021-2032) Figure 47. Asia Acute Hepatic Porphyria Drug Revenue Share by Application (2021-2032) Figure 48. Asia Acute Hepatic Porphyria Drug Revenue Share by Region (2021-2032) Figure 49. Japan Acute Hepatic Porphyria Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. South Korea Acute Hepatic Porphyria Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. India Acute Hepatic Porphyria Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Australia Acute Hepatic Porphyria Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Taiwan Acute Hepatic Porphyria Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Southeast Asia Acute Hepatic Porphyria Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. SAMEA Acute Hepatic Porphyria Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 56. SAMEA Acute Hepatic Porphyria Drug Revenue Share by Type (2021-2032) Figure 57. SAMEA Acute Hepatic Porphyria Drug Revenue Share by Application (2021-2032) Figure 58. SAMEA Acute Hepatic Porphyria Drug Revenue Share by Country (2021-2032) Figure 59. Brazil Acute Hepatic Porphyria Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Argentina Acute Hepatic Porphyria Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Chile Acute Hepatic Porphyria Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Colombia Acute Hepatic Porphyria Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Peru Acute Hepatic Porphyria Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Saudi Arabia Acute Hepatic Porphyria Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Israel Acute Hepatic Porphyria Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. UAE Acute Hepatic Porphyria Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Turkey Acute Hepatic Porphyria Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Iran Acute Hepatic Porphyria Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Egypt Acute Hepatic Porphyria Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • 350 Mg
  • 313 Mg
Applications
  • Retail Pharmacy
  • Online Pharmacy
  • Hospital Pharmacy
  • Others
Companies covered
  • Alnylam Pharmaceuticals
  • Recordati Rare Diseases

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Acute Hepatic Porphyria Drug Market by Type
  3. 1.2.1 Global Acute Hepatic Porphyria Drug Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 350 Mg
  5. 1.2.3 313 Mg
  6. 1.3 Acute Hepatic Porphyria Drug Market by Application
  7. 1.3.1 Global Acute Hepatic Porphyria Drug Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Retail Pharmacy
  9. 1.3.3 Online Pharmacy
  10. 1.3.4 Hospital Pharmacy
  11. 1.3.5 Others
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 Acute Hepatic Porphyria Drug Market Dynamics
  1. 2.1 Acute Hepatic Porphyria Drug Industry Trends
  2. 2.2 Acute Hepatic Porphyria Drug Industry Drivers
  3. 2.3 Acute Hepatic Porphyria Drug Industry Opportunities and Challenges
  4. 2.4 Acute Hepatic Porphyria Drug Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Acute Hepatic Porphyria Drug Market Perspective (2021-2032)
  2. 3.2 Global Acute Hepatic Porphyria Drug Growth Trends by Region
  3. 3.2.1 Global Acute Hepatic Porphyria Drug Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Acute Hepatic Porphyria Drug Market Size by Region (2021-2026)
  5. 3.2.3 Global Acute Hepatic Porphyria Drug Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Acute Hepatic Porphyria Drug Revenue by Players
  2. 4.1.1 Global Acute Hepatic Porphyria Drug Revenue by Players (2021-2026)
  3. 4.1.2 Global Acute Hepatic Porphyria Drug Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Acute Hepatic Porphyria Drug Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Acute Hepatic Porphyria Drug Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Acute Hepatic Porphyria Drug Key Players Headquarters & Area Served
  7. 4.4 Global Acute Hepatic Porphyria Drug Players, Product Type & Application
  8. 4.5 Global Acute Hepatic Porphyria Drug Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Acute Hepatic Porphyria Drug Market CR5 and HHI
  11. 4.6.3 2025 Acute Hepatic Porphyria Drug Tier 1, Tier 2, and Tier 3
5 Acute Hepatic Porphyria Drug Market Size by Type
  1. 5.1 Global Acute Hepatic Porphyria Drug Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Acute Hepatic Porphyria Drug Revenue by Type (2021-2032)
  3. 5.3 Global Acute Hepatic Porphyria Drug Revenue Market Share by Type (2021-2032)
6 Acute Hepatic Porphyria Drug Market Size by Application
  1. 6.1 Global Acute Hepatic Porphyria Drug Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Acute Hepatic Porphyria Drug Revenue by Application (2021-2032)
  3. 6.3 Global Acute Hepatic Porphyria Drug Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Alnylam Pharmaceuticals
  2. 7.1.1 Alnylam Pharmaceuticals Company Information
  3. 7.1.2 Alnylam Pharmaceuticals Business Overview
  4. 7.1.3 Alnylam Pharmaceuticals Acute Hepatic Porphyria Drug Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Alnylam Pharmaceuticals Acute Hepatic Porphyria Drug Product Portfolio
  6. 7.1.5 Alnylam Pharmaceuticals Recent Developments
  7. 7.2 Recordati Rare Diseases
  8. 7.2.1 Recordati Rare Diseases Company Information
  9. 7.2.2 Recordati Rare Diseases Business Overview
  10. 7.2.3 Recordati Rare Diseases Acute Hepatic Porphyria Drug Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Recordati Rare Diseases Acute Hepatic Porphyria Drug Product Portfolio
  12. 7.2.5 Recordati Rare Diseases Recent Developments
8 North America
  1. 8.1 North America Acute Hepatic Porphyria Drug Revenue (2021-2032)
  2. 8.2 North America Acute Hepatic Porphyria Drug Revenue by Type (2021-2032)
  3. 8.2.1 North America Acute Hepatic Porphyria Drug Revenue by Type (2021-2026)
  4. 8.2.2 North America Acute Hepatic Porphyria Drug Revenue by Type (2027-2032)
  5. 8.3 North America Acute Hepatic Porphyria Drug Revenue Share by Type (2021-2032)
  6. 8.4 North America Acute Hepatic Porphyria Drug Revenue by Application (2021-2032)
  7. 8.4.1 North America Acute Hepatic Porphyria Drug Revenue by Application (2021-2026)
  8. 8.4.2 North America Acute Hepatic Porphyria Drug Revenue by Application (2027-2032)
  9. 8.5 North America Acute Hepatic Porphyria Drug Revenue Share by Application (2021-2032)
  10. 8.6 North America Acute Hepatic Porphyria Drug Revenue by Country
  11. 8.6.1 North America Acute Hepatic Porphyria Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Acute Hepatic Porphyria Drug Revenue by Country (2021-2026)
  13. 8.6.3 North America Acute Hepatic Porphyria Drug Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Acute Hepatic Porphyria Drug Revenue (2021-2032)
  2. 9.2 Europe Acute Hepatic Porphyria Drug Revenue by Type (2021-2032)
  3. 9.2.1 Europe Acute Hepatic Porphyria Drug Revenue by Type (2021-2026)
  4. 9.2.2 Europe Acute Hepatic Porphyria Drug Revenue by Type (2027-2032)
  5. 9.3 Europe Acute Hepatic Porphyria Drug Revenue Share by Type (2021-2032)
  6. 9.4 Europe Acute Hepatic Porphyria Drug Revenue by Application (2021-2032)
  7. 9.4.1 Europe Acute Hepatic Porphyria Drug Revenue by Application (2021-2026)
  8. 9.4.2 Europe Acute Hepatic Porphyria Drug Revenue by Application (2027-2032)
  9. 9.5 Europe Acute Hepatic Porphyria Drug Revenue Share by Application (2021-2032)
  10. 9.6 Europe Acute Hepatic Porphyria Drug Revenue by Country
  11. 9.6.1 Europe Acute Hepatic Porphyria Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Acute Hepatic Porphyria Drug Revenue by Country (2021-2026)
  13. 9.6.3 Europe Acute Hepatic Porphyria Drug Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
10 China
  1. 10.1 China Acute Hepatic Porphyria Drug Revenue (2021-2032)
  2. 10.2 China Acute Hepatic Porphyria Drug Revenue by Type (2021-2032)
  3. 10.2.1 China Acute Hepatic Porphyria Drug Revenue by Type (2021-2026)
  4. 10.2.2 China Acute Hepatic Porphyria Drug Revenue by Type (2027-2032)
  5. 10.3 China Acute Hepatic Porphyria Drug Revenue Share by Type (2021-2032)
  6. 10.4 China Acute Hepatic Porphyria Drug Revenue by Application (2021-2032)
  7. 10.4.1 China Acute Hepatic Porphyria Drug Revenue by Application (2021-2026)
  8. 10.4.2 China Acute Hepatic Porphyria Drug Revenue by Application (2027-2032)
  9. 10.5 China Acute Hepatic Porphyria Drug Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Acute Hepatic Porphyria Drug Revenue (2021-2032)
  2. 11.2 Asia Acute Hepatic Porphyria Drug Revenue by Type (2021-2032)
  3. 11.2.1 Asia Acute Hepatic Porphyria Drug Revenue by Type (2021-2026)
  4. 11.2.2 Asia Acute Hepatic Porphyria Drug Revenue by Type (2027-2032)
  5. 11.3 Asia Acute Hepatic Porphyria Drug Revenue Share by Type (2021-2032)
  6. 11.4 Asia Acute Hepatic Porphyria Drug Revenue by Application (2021-2032)
  7. 11.4.1 Asia Acute Hepatic Porphyria Drug Revenue by Application (2021-2026)
  8. 11.4.2 Asia Acute Hepatic Porphyria Drug Revenue by Application (2027-2032)
  9. 11.5 Asia Acute Hepatic Porphyria Drug Revenue Share by Application (2021-2032)
  10. 11.6 Asia Acute Hepatic Porphyria Drug Revenue by Country
  11. 11.6.1 Asia Acute Hepatic Porphyria Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Acute Hepatic Porphyria Drug Revenue by Country (2021-2026)
  13. 11.6.3 Asia Acute Hepatic Porphyria Drug Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Acute Hepatic Porphyria Drug Revenue (2021-2032)
  2. 12.2 SAMEA Acute Hepatic Porphyria Drug Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Acute Hepatic Porphyria Drug Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Acute Hepatic Porphyria Drug Revenue by Type (2027-2032)
  5. 12.3 SAMEA Acute Hepatic Porphyria Drug Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Acute Hepatic Porphyria Drug Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Acute Hepatic Porphyria Drug Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Acute Hepatic Porphyria Drug Revenue by Application (2027-2032)
  9. 12.5 SAMEA Acute Hepatic Porphyria Drug Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Acute Hepatic Porphyria Drug Revenue by Country
  11. 12.6.1 SAMEA Acute Hepatic Porphyria Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Acute Hepatic Porphyria Drug Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Acute Hepatic Porphyria Drug Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst